Volume 4 | Issue 1 | DOI: https://doi.org/10.33696/cancerimmunol.4.059
MEK Inhibition in KRAS Mutated NSCLC: Quo vadis?
- 1Department of Oncology and Hematology, Cantonal Hospital St. Gallen, Rorschacher Strasse 95, 9007 St. Gallen, Switzerland
- 2Department of Life Technologies, University of Turku, FI-20520 Turku, Finland
- 3Department of Medical Oncology/Hematology, Cantonal Hospital Graubu?nden, Loëstrasse 170, 7000 Chur, Switzerland
- 4Department of Medical Oncology and Comprehensive Cancer Center, University Hospital Basel, Petersgraben 4, 4031 Basel,Switzerland
- 5Department of Medical Oncology, University of Berne, Bern, Switzerland
Kira-Lee Koster, Kira-Lee.Koster@kssg.ch
Received Date: December 21, 2021
Accepted Date: January 12, 2022
Koster KL, Froesch P, Mark M, Rothschild SI, Früh M. MEK Inhibition in KRAS Mutated NSCLC: Quo vadis? J Cancer Immunol. 2022;4(1):12-16.
Copyright: © 2022 Koster KL, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Prospective Evaluation of Effect of Metformin on Activation of AMP-activated Protein Kinase (AMPK) and Disease Control in a Sub-group Analysis of Patients with GI Malignancies
Observational studies have demonstrated association of metformin with reduced cancer incidence and mortality in multiple cancer types, including gastrointestinal (GI) malignancies. Anti-neoplastic effects of metformin are believed through many mechanisms including activation of AMP-activated protein kinase, which controls mammalian target of rapamycin (mTOR) growth regulatory pathway.
Primary Lymph Node Kaposi's Sarcoma in Two HIV Positive Patients Presenting with Generalized Lymphadenopathy and Pancytopenia in a Third Level Hospital in Guatemala
We present two unique cases in which two HIV positive patients with generalized lymphadenopathy and pancytopenia without any skin lesions were diagnosed with primary lymph node Kaposi´s Sarcoma after excisional biopsy of an inguinal lymph node.
Liposarcoma (LS) is the most common soft tissue sarcoma (20% of the tumors in adults). This neoplasm was first described by Virchow in 1857 and has been well documented thereafter. Liposarcoma is a common soft tissue malignant tumor and is often found in the lower extremities and retro peritoneum. Only about 5.6% of liposarcomas are found in the head and neck and most of these tumors arise from the soft tissues of the neck [1-3].
Treatment of Neurological Manifestations of Mucopolysaccharidoses: Translational Considerations in Drug Development
Since the development of Ceredase® and Cerezyme® for the treatment of Gaucher disease in the early 1990s, treatment of lysosomal storage disorders via enzyme replacement therapy (ERT) has provided life-changing benefit to patients and their families.
High Expression of TIM 3 and Galectin 9 on Immunohistochemistry Staining of Tumor Specimen at Diagnosis in Pediatric Patients with Ewing Sarcoma
The concept of immunotherapy has been traced as far back to third century BC Qin dynasty in China through the purposeful inoculation of Variola minor to prevent smallpox.